

Announcement: Appointment to the Board of Directors, Dr Peter Corr.

CBio is pleased to announce the appointment of Dr Peter Corr as a non-executive director. Dr. Corr retired from Pfizer Inc in 2007, where he served as Senior Vice President, Science & Technology. Previously, he was Executive Vice President, Pfizer Global Research & Development, and President, Worldwide Development. Prior, Dr. Corr was President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis until the merger with Pfizer) and he previously served as Senior Vice President, Discovery Research, at Monsanto/Searle.

Dr Corr is General Partner, Celtic Therapeutics Management Company L.L.L.P., a private equity firm focused on the development of innovative therapeutics, alliances that advance solutions for diseases of the developing world, and global advocacy for biomedical innovation. He has also spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis, where he was Professor of Medicine (Cardiology) and Professor of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts.

Dr. Corr serves on the Board of Governors of the New York Academy of Sciences (immediate past Chairman), the Board of Regents of Georgetown University, and several other non-profit and for-profit boards. He also is a member of the Institute Of Medicine's Forum on Drug Discovery, Development, and Translation.

The appointment of the internationally-recognised Dr Corr to the Board of CBio is a significant development and one which will further aid the company as it progresses its clinical trial and commercialisation program.

30 October 2007.